Troubled Genzyme launches probe into insider trading claims

With regulators negotiating a hefty fine for the issues that have plagued its Allston Landing plant, Carl Icahn at the gates demanding a top-level overhaul and patients in an uproar over continued shortages of its key product, Genzyme (NASDAQ: GENZ) can now add one more problem to its list: stockholder allegations that executives at the Big Biotech company engaged in insider trading. In a filing with the SEC, Genzyme said it has named three independent directors to a special committee...